← Back to patent-cliff list
CAS 16874-06-9
di-tert-butyl L-glutamate
Codes：PRAL-017
Application context (from source-drug indications)
外周T细胞淋巴瘤普拉曲沙T-细胞淋巴瘤普拉曲沙实体瘤普拉曲沙血液肿瘤普拉曲沙B-细胞淋巴瘤普拉曲沙皮肤T细胞淋巴瘤普拉曲沙
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 普拉曲沙Pralatrexate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid→methyl 4-formylbenzoate→methyl 5'-methyl-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylate→methyl 4-(6-oxohept-1-yn-4-yl)benzoate→dimethyl carbonate→methyl 4-(8-methoxy-6,8-dioxooct-1-yn-4-yl)benzoate→(E)-4-(7-(hydroxyimino)-6-oxohept-1-yn-4-yl)benzoic acid→pyrimidine-2,4,5,6-tetraamine hydrochloride→di-tert-butyl L-glutamate→di-tert-butyl (4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoyl)-L-glutamate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.